(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Soldiers seize power in Guinea-Bissau and detain the president- Figuring out the Business venture Code: The Response to Building an Effective Startup
- Deadly heat worldwide prompts $300 million for climate health research at COP30
- The most effective method to Promoter for Cellular breakdown in the lungs Mindfulness in Your People group
- A definitive Manual for Web based Mastering and Expertise Improvement
- Find the Advantages of Innovative Leisure activities: Supporting Creative mind and Self-Articulation
- 'Dancing With the Stars' Season 34 finale: Who might win the mirror ball trophy? Where do the remaining contestants rank?
- Elite Execution Wall televisions for Film Darlings
- Getting ready for a Mechanized World: 10 Positions That computer based intelligence Could Dominate
